Combining traditional agents and biologics for the treatment of psoriasis

被引:35
作者
Cather, JC
Menter, A
机构
[1] Baylor Univ, Med Ctr, Dallas, TX USA
[2] Texas Dermatol Assoc, Dallas, TX USA
关键词
D O I
10.1016/j.sder.2005.01.002
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis patients deserve long-term control of their disease with optimal safety. Traditional agents (methotrexate, cyclosporine, retinoids, and photochemotherapy [PUVS]), although providing excellent short-term control, may produce acute or chronic toxicities, thus limiting their usage. Dermatologists are well versed in combination and rotational therapies for psoriasis, using these and other agents. With the advent of biologic therapies (three currently approved, and others pending), the potential for safer long-term psoriasis control is being realized. A review of the literature, plus our personal experience in using combinations of traditional agents and biologics, is presented. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:37 / 45
页数:9
相关论文
共 59 条
[1]   Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis [J].
Barland, C ;
Kerdel, FA .
ARCHIVES OF DERMATOLOGY, 2003, 139 (07) :949-950
[2]   Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis [J].
Barrera, P ;
Joosten, LAB ;
den Broeder, AA ;
van de Putte, LBA ;
van Riel, PLCM ;
van den Berg, WB .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (07) :660-669
[3]   Immunomodulatory drugs for psoriasis - New "biologics" offer much promise [J].
Boehncke, WH .
BRITISH MEDICAL JOURNAL, 2003, 327 (7416) :634-635
[4]  
BRAY VJ, 2001, EMERGING ROLE INFLIX
[5]  
BREEDVELD FC, 2004, LONG TERM REMISSION
[6]  
CONDREANU C, 2003, DOUBLE BLIND COMP ET
[7]   Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis:: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation [J].
den Broeder, AA ;
Joosten, LAB ;
Saxne, T ;
Heinegård, D ;
Fenner, H ;
Miltenburg, AMM ;
Frasa, WLH ;
van Tits, LJ ;
Buurman, WA ;
van Riel, PLCM ;
van de Putte, LBA ;
Barrera, P .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (04) :311-318
[8]   Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial [J].
Ferraccioli, GF ;
Assaloni, R ;
Di Poi, E ;
Gremese, E ;
De Marchi, G ;
Fabris, M .
RHEUMATOLOGY, 2002, 41 (10) :1109-1112
[9]  
Fleischmann Roy M, 2004, Expert Opin Drug Saf, V3, P391, DOI 10.1517/14740338.3.5.391
[10]  
Furst DE, 2003, J RHEUMATOL, V30, P2563